Class IITerminatedD-0869-2023
Drug recall · June 14, 2023
Buprenorphine Sublingual Tablets recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.
- Lots / codes
Lot #: DND1515A, Exp 08/24
- Quantity
- 12,336 bottles
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Product was distributed to 19 distributors nationwide.
- Initiated
- May 3, 2023 · Voluntary: Firm initiated
- Classified
- June 7, 2023
- Reported
- June 14, 2023
- Ended
- January 9, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.